A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1b Safety Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Patients With Mild to Moderate Probable Alzheimer's Disease.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Phase 1b Safety Study of Three Different Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo in Patients With Mild to Moderate Probable Alzheimer's Disease.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Jun 2014

At a glance

  • Drugs Encenicline (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors EnVivo Pharmaceuticals; FORUM Pharmaceuticals
  • Most Recent Events

    • 06 Mar 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
    • 06 Mar 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Oct 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top